Insider Transactions in Q4 2025 at Immunovant, Inc. (IMVT)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2025
|
Christopher Van Tuyl Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,813
-3.4%
|
$291,951
$27.08 P/Share
|
|
Dec 12
2025
|
Roivant Sciences Ltd. |
BUY
Open market or private purchase
|
Direct |
16,666,666
+12.82%
|
$349,999,986
$21.0 P/Share
|
|
Dec 01
2025
|
Andrew J. Fromkin Director |
SELL
Open market or private sale
|
Direct |
22,249
-10.58%
|
$511,727
$23.55 P/Share
|
|
Dec 01
2025
|
Douglas J. Hughes Director |
SELL
Open market or private sale
|
Direct |
15,000
-5.6%
|
$345,000
$23.55 P/Share
|
|
Nov 20
2025
|
Melanie Gloria Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,626
-3.43%
|
$290,398
$23.76 P/Share
|
|
Oct 22
2025
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,520
-1.24%
|
$47,880
$19.03 P/Share
|
|
Oct 22
2025
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,595
-1.18%
|
$49,305
$19.03 P/Share
|
|
Oct 08
2025
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
1,585
-0.77%
|
$25,360
$16.3 P/Share
|
|
Oct 08
2025
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,272
-0.57%
|
$20,352
$16.3 P/Share
|